-
1 Comment
Zhejiang AngLiKang Pharmaceutical CO.,LTD is currently in a long term downtrend where the price is trading 10.7% below its 200 day moving average.
From a valuation standpoint, the stock is 72.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.7.
Zhejiang AngLiKang Pharmaceutical CO.,LTD's total revenue sank by 2.7% to $310M since the same quarter in the previous year.
Its net income has increased by 55.4% to $39M since the same quarter in the previous year.
Finally, its free cash flow grew by 49.7% to $45M since the same quarter in the previous year.
Based on the above factors, Zhejiang AngLiKang Pharmaceutical CO.,LTD gets an overall score of 3/5.
Sector | Healthcare |
---|---|
Industry | Drug Manufacturers - Specialty & Generic |
Exchange | SHE |
CurrencyCode | CNY |
ISIN | CNE100003GC2 |
PE Ratio | 39.32 |
---|---|
Target Price | None |
Dividend Yield | 1.6% |
Beta | 0.3 |
Market Cap | 3B |
Zhejiang AngLiKang Pharmaceutical CO.,LTD., a pharmaceutical company, engages in manufacturing APIs and pharmaceutical preparations for oral cephalosporins, cardiovascular, and kidney diseases. The company also offers products in the areas of anti-infection, antihypertensive, digestive system, central nervous diseases, and respiratory preparations. The company was founded in 2001 and is based in Shengzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002940.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025